Literature DB >> 15800022

Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

Sabine Cepok1, Berit Rosche, Verena Grummel, Friederike Vogel, Dun Zhou, Joachim Sayn, Norbert Sommer, Hans-Peter Hartung, Bernhard Hemmer.   

Abstract

Multiple sclerosis is a chronic inflammatory and demyelinating disorder of the CNS with an unknown aetiology. Although intrathecal immunoglobulin G (IgG) synthesis is a key feature of the disease, little is still known about the B cell response in the CNS of multiple sclerosis patients. We analysed the phenotype and kinetics of different B cell subsets in patients with multiple sclerosis, infectious disease (IND) and non-inflammatory neurological disease (NIND). B cells were detected in the CSF of multiple sclerosis and IND patients, but were largely absent in NIND patients. In the CSF, the majority of B cells had a phenotype of memory B cells and short-lived plasma blasts (PB); plasma cells were absent from the compartment. The proportion of PB was highest in multiple sclerosis patients and patients with acute CNS infection. While PB disappeared rapidly from the CSF after resolution of infection in IND patients, these cells were present at high numbers throughout the disease course in multiple sclerosis patients. CSF PB numbers in multiple sclerosis patients strongly correlated with intrathecal IgG synthesis and inflammatory parenchymal disease activity as disclosed by MRI. This study identifies short-lived plasma blasts as the main effector B cell population involved in ongoing active inflammation in multiple sclerosis patients.

Entities:  

Mesh:

Year:  2005        PMID: 15800022     DOI: 10.1093/brain/awh486

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  122 in total

1.  Intrathecally synthesized IgG in multiple sclerosis cerebrospinal fluid recognizes identical epitopes over time.

Authors:  Xiaoli Yu; Mark Burgoon; Miyoko Green; Olga Barmina; Kathryn Dennison; Tiffany Pointon; Molly Davis; Don Gilden
Journal:  J Neuroimmunol       Date:  2011-11-12       Impact factor: 3.478

Review 2.  Development of anti-CD20 therapy for multiple sclerosis.

Authors:  Beatrix Bartok; Gregg J Silverman
Journal:  Exp Cell Res       Date:  2011-04-12       Impact factor: 3.905

Review 3.  Viruses and multiple sclerosis.

Authors:  Gregory P Owens; Don Gilden; Mark P Burgoon; Xiaoli Yu; Jeffrey L Bennett
Journal:  Neuroscientist       Date:  2011-12       Impact factor: 7.519

Review 4.  Potential importance of B cells in aging and aging-associated neurodegenerative diseases.

Authors:  Arya Biragyn; Maria Aliseychik; Evgeny Rogaev
Journal:  Semin Immunopathol       Date:  2017-01-12       Impact factor: 9.623

5.  Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection.

Authors:  Christopher Harp; Jane Lee; Doris Lambracht-Washington; Elizabeth Cameron; Gregory Olsen; Elliot Frohman; Michael Racke; Nancy Monson
Journal:  J Neuroimmunol       Date:  2006-12-13       Impact factor: 3.478

Review 6.  Epstein-barr virus: environmental trigger of multiple sclerosis?

Authors:  Jan D Lünemann; Thomas Kamradt; Roland Martin; Christian Münz
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

Review 7.  B-cells and humoral immunity in multiple sclerosis. Implications for therapy.

Authors:  Sangjin Oh; Cornelia Cudrici; Takahiro Ito; Horea Rus
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 8.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

9.  Genetic variants in the immunoglobulin heavy chain locus are associated with the IgG index in multiple sclerosis.

Authors:  Dorothea Buck; Eva Albrecht; Muhammad Aslam; An Goris; Natalie Hauenstein; Angela Jochim; Sabine Cepok; Verena Grummel; Bénédicte Dubois; Achim Berthele; Peter Lichtner; Christian Gieger; Juliane Winkelmann; Bernhard Hemmer
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

Review 10.  [Targeting B cells in multiple sclerosis. Current concepts and strategies].

Authors:  T Menge; H-C Büdingen; M C Dalakas; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.